

:

:

---

:

:



	5
	6
	8
1.	9
1.1	9
1.2	10
2.	16
3.	19
3.1	19
3.2	21
3.3	24
3.3.1	24
3.3.1.1	27
3.3.2	33
3.3.2.1	
	35
3.3.2.2	
	37
3.4	39
3.5	42

4.	44
5.	47
	50
	51

1.	μ μ μ , μ	12
μ	.....	
2.	μ μ μ μ μ	15
μ	.....	
3.	μ μ	22
	μ	.....
4.	μ	26
-	.....	
5.	μ 2011,	47
6.	μ 2011,	
Mesotherapy Center Atlanta.....		48
7.	μ 2011,	
	μ	.....
		48

1.	Dr Michel Pistor.....	10
2.	μ .....	19
3.	μ .....	21
4.	μ μ μ μ .....	24
5.	μ μ .....	25
6.	μ μ μ μ μ μ .....	26
7.	μ .....	27
8.	μ μ μ μ .....	28
A)	57 μ μ .....	
B)	μ μ phosphatidylcholine μ 30 μ .....	
C)	μ μ phosphatidylcholine μ 60 μ .....	
D)	μ μ phosphatidylcholine μ 120 μ .....	
9.	μ μ μ .....	30
10.	μ μ μ .....	31
11.	μ μ .....	31
12.	μ μ .....	31
13.	μ μ .....	33
14.	μ μ μ μ μ 56 (4 μ ).....	35

15.	μ μ μ μ	28	(μ 6 8	
μ )	.....			36
16.	μ μ μ μ		56	
(μ 10 μ )	.....			36
17.	μ μ μ μ			37
18.	μ μ μ μ	53	μ 10	
μ	.....			38
19.	μ μ μ μ	41	μ 10	
μ	.....			38
20.	μ μ μ μ	46	μ 7	
μ	.....			39
21.				
) μ μ μ μ			μ sodium deoxycholate	
(10mg/mL) μ μ			(Lee, Chang, 2005).	
) μ μ			μ	
μ μ			<i>Mycobacteria chelonae</i> .....	41
22. μ μ μ μ			μ 8	.....42





# 1.

μ , μ μ . μ  
μ μ μ ( , μ μ ,  
μ , μ ) μ ,  
μ μ .  
«μ » μ μ μ , μ  
μ μ (Le Coz, 2005).

μ  
μ μ (Rotund, Kolodney, 2006). μ  
μ μ .  
μ μ μ .  
μ μ μ .  
μ , μ μ μ  
μ . μ μ  
μ , μ μ μ  
μ . μ μ μ ,  
μ μ μ  
μ (Kaplan, 1985).

## 1.1

μ , 400 . μ μ  
μ μ . μ  
2000 , μ μ  
19 (Matarasso, Pfeifer, 2005).

μ μ μ ,  
 μ , Dr Michel Pistor (1924-2003), μ μ  
 (Pistor, 1976). O Pistor  
 μ “Legion d’ Honneur”, μ

Dr Michel Pistor

μ μ μ . μ ,  
 μ  
 μ Dr Michel Pistor μ 3-5 mm,  
 μ  
 (Le Coz J, 2005).



1. Dr Michel Pistor

## 1.2

Dr. Michel Pistor

μ μ  
 μ μ Michel Pistor 1948  
 1952. μ , μ

Pistor μ μ μ 1958.

μ μ μ , μ μ μ

μ μ .

μ μ μ μ μ μ μ

1987. μ μ μ .

μ μ μ 18.000 μ .

μ μ μ μ μ μ μ

μ . μ μ μ ,

μ , μ μ μ

μ μ μ .

μ Rotunda Kolodney (2006) μ

μ μ :

- T3-T4 thyroid,
- Isoproterenol
- Aminophylline
- Pentoxifylline
- L-carnitine
- L-arginine
- Hyaluronidase
- Collagenase
- Yohimbine
- Lymphomyosot
- Co-enzyme cofactors
- Dimethylethanolamine
- Gerovital



	Orphenadrine-	
	μ	μ
μ	μ	NSAIDs
		μ
	EDTA	μ
	Buflomedil	
	μ	
	, Ginko biloba, melilotus, μ , Arnica	
	Tretinoin	
μ	-	μ
μ μ μ	Finesteride	5 -
	Minoxidil	

	Vaccines	
	μ - ,	-
		μ
		Krebs
		μ
	Ma huang	
	3/ 4	μ
	μ ( , , , , )	
	(Se, Zn, Mg, Cr), -	
		μ
	DMAE ( μ μ )	





## 2.


μ ,  
μ .  
μ μ  
μ μ  
μ , μ , μ μ melilotus  
μ μ  
μ μ μ (Caruso et al, 2006).  
μ μ μ :  
μ , μ μ ,  
μ μ . μ  
μ (Dr. Avram, 2004).  
μ μ Dr Heinrick (2009), μ μ μ 100 μ ( )  
μ μ μ  
μ ,  
μ , μ (Asaadi et al, 2004)  
μ μ  
μ μ . 2005 Rose & Morgan, μ  
μ μ μ PC  
DC  
μ μ μ  
μ μ μ  
(Amin et al, 2006), μ  
(Ismail, 2007).  
μ μ  
μ μ μ

. μ μ (Duve et al, 2010).  
 μ μ  
 μ ,  
 μμ μ .  
 , μ μ ,  
 μ , μ  
 (Hasegawa et al, 2009). , μ μ μ  
 μ μ μ  
 μ μ μ (Montalvan et al,  
 2004).  
 μ μ  
 μ μ μ  
 μ μ , (Razan  
 et al, 2008). , μ μ Nagore (2001)  
 μ μ *Mycobacterium fortuitum* μ μ  
 μ (Urbani, 1994).  
 2006 Rivera-Olivero ,  
 μ *Mycobacterium* sp. μ μ , μ  
 (Munayco, 2008), μ μ μ *Mycobacterium chelonae*  
 μ μ . Dr Brown (2006),  
 μ μ ,  
 μ .  
 μ μ  
 , μ μ  
 μ μ (Kronemyer, 1999).  
 , μ μ μ μ  
 μ μ  
 , μ μ  
 μ μ , μ μ  
 (Tosti & Padova, 2007). μ μ  
 .  
 μ , μ μ ,

μ , μ (Chase,  
2005). μ μ  
μ .  
μ (Herreros et al, 2010). μ  
μ , μ  
μ . μ  
μ μ .  
μ , μ .  
μ μ (Bishara  
et al, 2008).







### 3. μ

μ μ .  
 , , ,  
 . μ μ  
 ,

μ ,  
 μ ( , 2001).

### 3.2

μ μ μ , μ  
 . μ , μ  
 μ . μ μ  
 μ μ μ ,  
 μ , μ , μ  
 μ , μ  
 μ μ .  
 μ , μ ,  
 μ μ μ μ μ , μ

μ - μ ,  
 μ  
 μ μ ( μ , , , ,  
 ). , μ μ μ ,  
 μ μ μ μ ,  
 μ μ , μ  
 (Bryant, 2004).

3. μ μ  
 μ . (Rosina, 2001).

μ	
μ	
	μ
μ	μ
:	
μ ,	
μ	
	μ
	μ

	$\mu$
	$\mu$
	$\mu$
	$\mu \quad \mu$
	$( \dots \mu\mu ,$ $)$
	$\mu \quad -$





. μ 45° μ  
 μ . μ .  
 — μ —  
 , μ , μ μ  
 1mm. , μ μ μ μ  
 μ μ . μ ,  
 . μ μ μ ,  
 μ μ μ μ μ ,  
 μ μ , μ μ  
 , μ , μ .  
 , μ , μ


(Leibaschoff, 2006).



5. μ μ

, μ μ ,  
 μ 10min 30min

(Le Coz J, 2008).



6. μ μ μ μ μ μ

4. μ -  
 (Rotunda, Kolodney, 2006).

		(mm)	μ μ
μ	μ	4	- 2 μ 10
		4, 6	10 15 μ
μ μ	μ	4	,



(Lyritis,2002).

μ (1%) μ (1%) μ buflomedil  
pentoxifylline, μ ,  
μ , gingo biloba melilotus  
μ (Polermo et al, 1991).

μ μ , μ , μ ,  
μ , μ .  
μ μ , μ μ μ μ



8. μ μ μ μ

A) 57 μ μ

B) μ μ phosphatidylcholine μ 30  
μ

C) μ μ phosphatidylcholine μ  
60 μ

D) μ μ phosphatidylcholine μ  
120 μ

μ  
, μ μ  
(« », « μ »). μ μ ,  
, μ μ . μ ,  
μ μ μ  
( « ») μ μ  
( ), ,  
, μ  
μ (μ μ ).  
μ μ μ μ μ  
μ μ μ .  
μ :

- 
- μ
- 
- μ .

μ μ « »  
μ (5-15) μ μ μ . μ

μ  
 , μ / .  
 μ μ μ  
 μ ( μ , , μ ), μ  
 μ ( , ) ( ,  
 2010).



9. μ μ μ

μ μ , μ μ  
 ( ) ( μ - μ - μ  
 , μ μ , μ  
 μ μ , μ μ  
 . μ , μ  
 μ . μ  
 , μ μ  
 μ μ μ .

μ , , μ μ μ μ  
 ( , μ , μ . . ) μ  
 μ μ .  
 μ μ μ μ μ  
 μ , , μ , μ μ ,  
 μ , , μ , μ .  
 μ - μ  
 μ μ μ μ μ μ  
 μ , μ μ μ μ μ μ .



10. μ μ μ



11. μ μ





12. μ μ



13. μ μ

, μ μ , μ μ  
( μ ) μ μ . μ μ  
μ μ , μ  
(Rohrich, 2005).

3.3.2

μ μ μ μ μ μ  
μ μ μ μ .  
μ , ' μ μ μ  
. ' μ μ μ ,  
μ μ μ μ .  
μ μ μ μ μ μ  
μ . μ μ μ μ μ μ  
μ , μ μ μ μ μ .  
μ μ μ μ μ , μ  
“Aquaphoresis”, μ laser LED μ ,  
μ







15. μ μ μ μ 28 (μ 6 8 μ )



16. μ μ μ μ 56 (μ 10 μ )







20. μ μ μ μ 46 μ 7  
μ


### 3.4

μ μ μ μ ,  
μ μ μ μ  
μ , μ .  
μ μ μ μ ,  
μ μ μ μ μ μ ,  
μ μ μ μ μ μ (Le Coz J,  
2009).

μ , μ , , μ μ , μ ,  
μ .  
· ,  
, μ μ  
(Chase, 2005).







21.

) μ μ μ μ μ sodium deoxycholate  
 (10mg/mL) μ μ (Lee, Chang, 2005).

) μ μ μ  
 μ μ Mycobacteria chelonae

, μ

μ , μ

μ μ μ : μ  
 • μ :

• : , μ μ μ  
 μ μ

• μ : μ  
 μ . μ  
 μ . μ 60-80 mcg μ

μ . μ  
 • , μ μ . (Sanudo et al, 2007).









•  $\mu$   $\mu$  , ,  
 • 2  $\mu$   
 ,  $\mu$   
 $\mu$   $\mu$   $\mu$   $\mu$  .  
 $\mu$   $\mu$  ,  $\mu$   $\mu$   $\mu$   $\mu$   $\mu$   
 $\mu$   $\mu$   $\mu$

([www.mesotherapy.com/cellulite](http://www.mesotherapy.com/cellulite)).

## 5.

μ  
 μ . , μ μ μ ,  
 μ ,  
 , μ , μ  
 μ  
 ( , μ ).  
 ,  
 μ ,  
 μ μ μ ,  
 μ 180 / , μ μ μ 300 /  
 80 / .

### 5. μ 2011,

	μ
	250-300 /
Athens Vision	150 /
Vita	1250 / 8
Cosmetic derma medicine	80 /
Betty' s spa	100 / 3
Only Beauty	65 /



www.costhelper.com  
 350\$  
 250\$ 450\$.  
 2.500\$ - 4000\$.  
 250\$ 450\$.  
 2.500\$ - 4000\$.

6. Mesotherapy  
 Center Atlanta

	\$300 μ \$399
	\$300 to \$399
	\$249
Botox	\$99
μ	\$195
μ	\$155 / \$325

7. 2011,  
 μ

μ		μ μ
3000\$	Boston	2
800\$	Chicago	6 μ

800\$	New York	$\mu$ 2
2500\$	New York	8-9 $\mu$
260\$	San Antonio, TX	$\mu$
1600\$	Watertown, SD	$\mu$ 5 $\mu$
1100\$	Atlanta, GA	4
550\$	Miami, Florida	2
120\$	Mindland, Texas	1 $\mu$
500\$	Miami, Florida	2

μ μ μ , μ μ ,  
μ μ , μ μ , μ  
, μ , μ  
μ , μ μ μ .  
μ , μ μ μ μ  
μ , μ ,  
μ , μ μ .  
μ μ μ μ  
μ μ , μ  
μ μ μ μ ,  
, μ μ  
.  
Η μ μ μ μ ,  
μ μ μ μ .  
μ μ , μ  
μ μ μ μ .  
μ μ μ μ  
μ .  
μ , μ , μ  
μ μ ,  
μ μ ,  
, μ μ μ  
μ .

- 
1. , . (2006). μ ,
  2. , . (2001). μ μ .  
μ , μ μ ,
  3. , ., (2010). μ – , Available  
from:
  4. , μ , . <http://www.mylook.gr/medical-and/skin/therapies/1/mesotherapeia.html>

- 
5. Adelson, H. (2006). French Mesotherapy for the treatment for the Treatment of Pain, VM Vol 4: 57
  6. Amin, S, P., Phelps, G, R., Goldberg, D, J. (2006). Mesotherapy for Facial Skin Rejuvenation: A Clinical, Histologic, and Electron Microscopic Evaluation, Dermatologic Surgery, Vol 32: 1467-1472
  7. Asaadi, M., Salas, P., Motamedi, B. (2004). Mesotherapy: A new approach to non-surgical liposculprure
  8. Bishara, S, A, ., Ibrahim, E, A., Saad A, D. (2008). Cosmetic Mesotherapy: Between Scientific Evidence, Science Fiction, and Lucrative Business, Aesthetic Plastic Surgery, Vol 32: 842-849
  9. Brown, S, A. (2006). The science of mesotherapy, Chemical anarchy. Aesthetic Surgery Journal, Vol 26: 95-98
  10. Bryan, R. (2004). Controversial mesotherapy: Could it be the next Botox? Derm Times 25: 1

11. BTL - Medical Aesthetics. (2008). No – needle mesotherapy, Available from: [www. Btlaesthetics.com](http://www.Btlaesthetics.com)
12. Caruso, J., Roberts, J., Bissoon, J., Self, J., Guillot, S., Greenway F, L. (2006). An evaluation of mesotherapy solutions for inducing lipolysis and treating cellulite
13. Centers for Disease Control and Prevention.(2005). Outbreak of mesotherapy-associated skin reactions FDistrict of Columbia area, Morb Mortal Wkly Rep 54:1127–30.
14. Chase, C, C. (2005). Common complications and adverse reactions in a mesotherapy practice. Available from: [www.mesotherapyworldwide.com/images/pdf/AJM\\_Vol\\_1\\_200510\\_8pdf](http://www.mesotherapyworldwide.com/images/pdf/AJM_Vol_1_200510_8pdf)
15. Duve, S., Schopperley, H., Niederdorfe, W. (2010). Mesotherapy and Hair Loss, Haut – Und Laserzentrum an der oper
16. Hasegawa, T., Matsukura, T., Ikeda, S. (2009). "Mesotherapy for Benign Symmetric Lipomatosis". *Aesthetic Plast Surg* **34** (2): 153–6. Kaplan, R. (1985). Devenir diun produit marquee injecte par quatre voies differentes. Bulletin SFM 62
17. Heinrick, J. (2009). New study involving 100 patients – Fat away injections, Kosmetische Chirurgie
18. Herreros, F., Machado de Moraes, A., Velho, P. (2010). Mesotherapy: a bibliographical review, UNICAMP, Sao Paulo, Brazil
19. Ismail, A. (2007). Mesotherapy in Dermatology, American Academy of Aesthetic Medicine
20. Kadry, R., Hamadah, I., Al-Issa, A., Field, L., Alrabiah, F. (2008). Multifocal scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy, *Journal of Drugs in Dermatology*
21. Kronemyer, B (1999). Derma Wave No-needle Mesotherapy eliminates negative side effects, *Aesthetic Buyers Guide*
22. Lee, DP., Chang, SE. (2005). Subcutaneous nodules showing fat necrosis owing to mesotherapy.*Dermatol Surg* 31: 250–1.

23. Leibaschoff, G. (2006). Mesotherapy and Cellulite. American Journal of Mesotherapy, Vol 4: 53
24. Le Coz (2005). History of Mesotherapy. Available from [www.mesotherapyworldwide.com/images/pdf/AJM Vol 3, 2005 11 40. pdf](http://www.mesotherapyworldwide.com/images/pdf/AJM_Vol_3_2005_11_40.pdf)
25. Le Coz (2008). Mesotherapy and Lipolysis, A Comprehensive clinical approach, 1<sup>st</sup> edition, Singapor, National Library Board
26. Le Coz and Ritter PG.(2009). Guidelines and limitations on the use of phosphatidylchlorine in mesotherapy. Available from: [www.mesotherapyworldwide.com/images/pdf/Vol. 20\\_2](http://www.mesotherapyworldwide.com/images/pdf/Vol_20_2)
27. Lyriis, G. P., Trovas, G. (2002). Analgesic effects of calcitonin. Bone 30: 71S-74S
28. Marco-Bonnet, J., Beylot-Barry, M., Texier-Maugein J. (2002). Mycobacterial bovis BCG cutaneous infections following mesotherapy: 2 cases. Ann Dermatol Venereol Vol 129:728–31.
29. Matarasso, A., Pfeifer, T, M. (2005). Plastic Surgery Educational Foundation Data Committee, Mesotherapy for body coutouring, 115: 1420-24
30. Medioni, G. (1976). Oro dental mesotherapy. Chir Dent Fr, Vol 46: 97-102
31. Montalvan, B., Parier, J., Laurens, D. (2004). The use of Mesotherapy in Sports Medicine, Paris
32. Munayco, C, V., Grijalva, C, G., Culqui, D, R., (2008). Outbreak of persistent cuntaneous abscesses due to Mycobacterium chelonae after mesotherapy session, Lima Peru, Rev. Saude. Publica, Vol 42: 146-149
33. Nagore, E., Ramos, P., Botella-Estrada, R., Ramos, J. (2001). Cutaneous Infection with Mycobacterium fortuitum after Localized Microinjections (Mesotherapy) Treated Successfully with a Triple Drug Regimen, Acta Derm Venereol, Vol 81: 291-293
34. Paul, C., Burguiere A,M., Vincent, V., Susbielle, P., Bonvalet, D., Dubertret, L. (1997). BCG induced mycobacterium infection induced by alternative medicine. Ann Dermatol Venereol 124:710–2.
35. Pistor, M. (1976). What is Mesotherapy, Chir Dent Fr. 46: 59-60

36. Pistor, M. (1979). Un def therapeutique. La mesotherapie. 3<sup>rd</sup> ediion, Paris, France: Malonie
37. Polermo, S., Riello, R., Cammardell, P., Carossino, D., Orlandini, G., Casigliani, R. (1991). Mesotherapy association in the therapy of cervico-brachialgia: Preliminary data. *Minerva Anesthesiol* 57: 1084-85
38. Rivera-Olivero, I, A., Guevara, A., Escalona, A. (2006). Soft tissue infection due to non-nontuberculous mycobacteria following mesotherapy. *Enferm. Infecc. Microbiol. Clin Vol* 24: 302-306.
39. Rohrich, R. J. (2005). Mesotherapy: What is is? Does it work? *Plast Reconst Surg*, Vol 32: 1467-72
40. Rose, P, T., Morgan, M. (2005). Historical changes associated with mesotherapy for fat dissolution. *Journal of cosmetician laser therapy*, Vol 7:17-19
41. Rosina P, Chierigato C, Miccolis D, D'Onghia FS. (2001). Psoriasis and side-effects of mesotherapy. *Int J Dermatol* 40:581–3.
42. Rotunda A,M., Kolodney M,S. (2006). Mesotherapy and phosphatidylcholine injections: historical clarification and review. *Apr*;32(4):465-80.
43. Sanudo, A., Valljo, F., Sierra, M., Hoyos, J, G., Yepes, S., Wolff, J.C. (2007). Nontuberculous mycobacteria infection after mesotherapy: Preliminary report of 15 cases. *Int J Dermatol.* 46:649-53
44. Tanrikuly, C. (2007). Medical education, *Turk Klinikleri J med Sci Vol* 27: 272-5
45. Tosti, A., Padova, M. (2007). *Atlas of Mesotherapy in Skin Rejuvenation*
46. Urbani, C, E. (1994). Urticarial reaction to ethylenediamine in aminophylline following mesotherapy, *Contact Dermatitis*, Vol 31: 198–199,
47. What is mesotherapy, Bissoon, L. <http://www.mesotherapy.com/cellulite/>